Littérature scientifique sur le sujet « SphK-1 »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « SphK-1 ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "SphK-1"
Venkataraman, Krishnan, Shobha Thangada, Jason Michaud, Myat Lin Oo, Youxi Ai, Yong-Moon Lee, Mingtao Wu et al. « Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient ». Biochemical Journal 397, no 3 (13 juillet 2006) : 461–71. http://dx.doi.org/10.1042/bj20060251.
Texte intégralWadgaonkar, Raj, Vipul Patel, Natalia Grinkina, Carol Romano, Jing Liu, Yutong Zhao, Saad Sammani, Joe G. N. Garcia et Viswanathan Natarajan. « Differential regulation of sphingosine kinases 1 and 2 in lung injury ». American Journal of Physiology-Lung Cellular and Molecular Physiology 296, no 4 (avril 2009) : L603—L613. http://dx.doi.org/10.1152/ajplung.90357.2008.
Texte intégralSerrano-Sanchez, Martin, Zahra Tanfin et Denis Leiber. « Signaling Pathways Involved in Sphingosine Kinase Activation and Sphingosine-1-Phosphate Release in Rat Myometrium in Late Pregnancy : Role in the Induction of Cyclooxygenase 2 ». Endocrinology 149, no 9 (29 mai 2008) : 4669–79. http://dx.doi.org/10.1210/en.2008-1756.
Texte intégralMEACCI, Elisabetta, Francesca CENCETTI, Chiara DONATI, Francesca NUTI, Laura BECCIOLINI et Paola BRUNI. « Sphingosine kinase activity is required for sphingosine-mediated phospholipase D activation in C2C12 myoblasts ». Biochemical Journal 381, no 3 (27 juillet 2004) : 655–63. http://dx.doi.org/10.1042/bj20031636.
Texte intégralAGEITOS, ARACELI TOBIO, GEETHANI BANDARA, ROSA MUNOZ-CANO, YUZHI YIN, AVANTI DESAI, DEAN METCALFE et ANA OLIVERA. « Sphingosine Kinase Inhibitors Effectively Inhibit Growth of Mast Cells with D816V-KIT Mutations ». Journal of Immunology 198, no 1_Supplement (1 mai 2017) : 145.13. http://dx.doi.org/10.4049/jimmunol.198.supp.145.13.
Texte intégralMagli, Elisa, Angela Corvino, Ferdinando Fiorino, Francesco Frecentese, Elisa Perissutti, Irene Saccone, Vincenzo Santagada, Giuseppe Caliendo et Beatrice Severino. « Design of Sphingosine Kinases Inhibitors : Challenges and Recent Developments ». Current Pharmaceutical Design 25, no 9 (9 juillet 2019) : 956–68. http://dx.doi.org/10.2174/1381612825666190404115424.
Texte intégralLynch, Kevin R. « Building a better sphingosine kinase-1 inhibitor ». Biochemical Journal 444, no 1 (26 avril 2012) : e1-e2. http://dx.doi.org/10.1042/bj20120567.
Texte intégralKharel, Yugesh, Mithun Raje, Ming Gao, Amanda M. Gellett, Jose L. Tomsig, Kevin R. Lynch et Webster L. Santos. « Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate ». Biochemical Journal 447, no 1 (12 septembre 2012) : 149–57. http://dx.doi.org/10.1042/bj20120609.
Texte intégralVessey, Donald A., Luyi Li, Zhu-Qiu Jin, Michael Kelley, Norman Honbo, Jianqing Zhang et Joel S. Karliner. « A Sphingosine Kinase Form 2 Knockout Sensitizes Mouse Myocardium to Ischemia/Reoxygenation Injury and Diminishes Responsiveness to Ischemic Preconditioning ». Oxidative Medicine and Cellular Longevity 2011 (2011) : 1–8. http://dx.doi.org/10.1155/2011/961059.
Texte intégralJo, Hyein, Kyeonghee Shim et Dooil Jeoung. « The Crosstalk between FcεRI and Sphingosine Signaling in Allergic Inflammation ». International Journal of Molecular Sciences 23, no 22 (11 novembre 2022) : 13892. http://dx.doi.org/10.3390/ijms232213892.
Texte intégralThèses sur le sujet "SphK-1"
Almeida, Ana Carolina de. « Expressão de SIRP'alfa' e SPH-1 na anemia hemolitica autoimune ». [s.n.], 2009. http://repositorio.unicamp.br/jspui/handle/REPOSIP/308297.
Texte intégralTese (doutorado)- Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-13T18:06:47Z (GMT). No. of bitstreams: 1 Almeida_AnaCarolinade_D.pdf: 1227023 bytes, checksum: 25438a379e180eeb0d1972b464b909b0 (MD5) Previous issue date: 2009
Resumo: SIRP 'alfa'(Signal Regulatory Protein 'alfa') é um receptor que medeia funções inibidoras em fagócitos. Sua ativação e conseqüente fosforilação dos ITIMs ocorre pela ligação ao CD47 presente na membrana dos eritrócitos, e permite o recrutamento e a ativação de SHP-1, a qual desfosforila substratos específicos envolvidos na mediação de diversos efeitos fisiológicos. O objetivo deste trabalho foi avaliar o papel da dexametasona (dexa) e de IFN?/TNFa sobre a expressão de SIRPa e SHP-1; a consequência desta regulação sobre a eritrofagocitose; e o nível de expressão gênica de SIRPa e SHP-1 em monócitos de pacientes com anemia hemolítica autoimune (AHAI) antes e depois de corticoterapia. Monócitos de doadores sadios e células mielomonocíticas U937 foram cultivados por 48 horas com dexa (1µM) ou IFN? (100U/ml) e TNFa (1000U/ml), por 6 horas com Hemina® (30uM), ou por 72 horas com prednisolona (0,15 e 1mg/l). Monócitos foram isolados de pacientes com AHAI antes e depois da corticoterapia. A expressão gênica de SIRPa e SHP-1 foi determinada por PCR em Tempo Real, a expressão protéica de SIRPa e SHP-1 foi determinada por Western Blotting, e a capacidade de eritrofagocitose foi determinada por microscopia. IFN? e TNFa, in vitro, promoveram o aumento da expressão gênica e protéica de SIRPa e a expressão gênica de SHP-1, em paralelo com a redução da capacidade de eritrofagocitose em monócitos normais. Em contrapartida, embora tenha aumentado a expressão gênica de SIRPa e SHP-1, dexa in vitro não alterou a expressão destas proteínas, assim como não alterou a capacidade de eritrofagocitose de monócitos normais. A expressão gênica de SIRPa e SHP-1 foi maior em monócitos de pacientes com AHAI em comparação a doadores sadios. Após corticoterapia, a expressão gênica de SIRPa e SHP-1 em monócitos de pacientes com AHAI se mostrou similar a doadores sadios. Pacientes com AHAI estudados antes da corticoterapia apresentaram baixos níveis de hemoglobina e após corticoterapia esse índice de mostrou normal. A expressão gênica de SIRPa foi aumentada pela cultura de monócitos com hemina, mas a expressão de proteína permaneceu a mesma. Nossos resultados confirmam o papel fundamental da SIRPa na regulação da eritrofagocitose e sugere que a expressão de mRNA de SIRPa em monócitos de pacientes com AHAI antes de corticoterapia é aumentada pela liberação de heme, e que a redução da expressão gênica de SIRPa após corticoterapia se deve a um efeito indireto desta droga pela redução da eritrofagocitose e diminuição da disponibilidade de heme.
Abstract: SIRPa (Signal Regulatory Protein a) is an inhibitory receptor in phagocytes. Its activation and consequent phosphorylation of ITIMs occurs by the binding to CD47 on erythrocyte membrane, what allows SHP-1 recruitment, which dephosphorylates specific substrates involved in the mediation of several physiologic effects. The aim of this work was to determine the role of dexamethasone and IFN?/TNFa upon SIRPa and SHP-1 expression, and the consequence of this regulation over erythrophagocytosis; and to evaluate the regulation of SIRPa and SHP-1 in peripheral blood monocytes (PBM) of autoimmune hemolytic anemia (AIHA) patients before and after glucocorticoid (GC) therapy. PBM from healthy donors and U937 myelomonocytic cells were cultured for 48 hours with dexamethasone (1µM) or IFN? (100U/ml) and TNFa (1000U/ml), for 6 hours with Hemin (30uM), or for 72 hours with prednisolone (0.15 and 1mg/l). PBM were isolated from AIHA patients under GC therapy or not. SIRPa and SHP-1 gene expression was determined by Real Time PCR, SIRPa and SHP-1 protein level was determined by Western Blotting, and erythrophagocytosis was determined by microscopy. IFN? and TNFa increased SIRPa gene and protein expression and SHP-1 gene expression, in parallel with a decrease in erythrophagocytosis ability in PBM. On the other hand, although SIRPa and SHP-1 gene expression was significantly increased, dexamethasone did not alter SIRPa and SHP-1 protein expression, and did not alter erythrophagocytosis ability in monocytes. SIRPa and SHP-1 expression was significantly higher in PBM from AIHA patients compared to normal. After GC therapy, SIRPa and SHP-1 expression was similar in PBM of AIHA patients compared to healthy donors. AIHA patients studied before glucocorticoid therapy showed low hemoglobin and after glucocorticoid therapy the level of hemoglobin was normal. SIRPa gene expression was increased by culture with hemin, but protein expression remained the same. Our results confirm the key role of SIRPa in erythrophagocytosis regulation and suggest that SIRPa mRNA expression in AIHA patients before glucocorticoid therapy is increased by heme release, and the decrease of SIRPa gene expression after glucocorticoid therapy is due to an indirect effect of this drug by the reduction of erythophagocytosis and free heme availability.
Doutorado
Doutor em Farmacologia
Le, Scolan Erwan Pierre Laurent. « Recherche d'altérations génétiques impliquées dans la transformation des proérythroblastes transgéniques pour spi-1 : dérégulation transcriptionnelle du gène codant pour la sphingosine kinase de type 1 ». Paris 7, 2005. http://www.theses.fr/2005PA077035.
Texte intégralZhang, Xiwen. « KNOCKOUT OF SPHINGOSINE KINASE 1 ATTENUATES RENAL INTERSTITIAL FIBROSIS IN UNILATERAL URETERAL OBSTRUCTION (UUO) MODEL ». VCU Scholars Compass, 2017. http://scholarscompass.vcu.edu/etd/5010.
Texte intégralGomez-Brouchet, Anne. « Rôle de la Sphingosine Kinase 1 (SphK1) dans la régulation de la survie des cellules de neuroblastome exposées au peptide Béta-amyloïde ». Toulouse 3, 2007. http://www.theses.fr/2007TOU30251.
Texte intégralAlzheimer disease (AD) is a critical problem of public health in the industrialized countries. AD affects 24. 3 million individuals in the world. In France, the number of AD patients represents 5 % of the population over 65 years-old (20 % of people over 85 years-old). Important progress have been made during the last ten years: Mutations were characterized, as well as genetic or environmental risk factors. A better analysis of the two elementary lesions of AD in their distribution and molecular characterization has allowed a better comprehension of the disease. Thus, the description of a dysfunction of proteins APP (Amyloid Precursor Protein) and Tau in sporadic and familial AD has led to therapeutic experiments and tests on cellular or animal models with promising results. Even though the diagnosis of AD still remains related to the neuropathology, it is evoked more precociously due to the progress in neuropsychological evaluation and imaging procedures. The advances in the comprehension of the disease mechanisms should make possible the discovery of new therapeutic targets. .
Drosos, Zacharias [Verfasser], Lars [Akademischer Betreuer] Hanker et Markus [Akademischer Betreuer] Meier. « Die prognostische Bedeutung der Expression von Acid-Ceramidase (ASAH1) und Sphingosin-Kinase 1 (SPHK1) bei Patientinnen mit Ovarialkarzinom / Zacharias Drosos ; Akademische Betreuer : Lars Hanker, Markus Meier ». Lübeck : Zentrale Hochschulbibliothek Lübeck, 2021. http://d-nb.info/1236386272/34.
Texte intégralBöhm, Andreas [Verfasser], Bernhard [Akademischer Betreuer] Rauch et Joachim [Akademischer Betreuer] Ernst. « Regulation der Sphingosin-Kinase 1 (SPHK1) durch den aktivierten Gerinnungsfaktor X (FXa) und den Protease-aktivierten Rezeptor 2 (PAR-2) in glatten Gefäßmuskelzellen / Andreas Böhm. Gutachter : Bernhard Rauch ; Joachim Ernst ». Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2013. http://d-nb.info/1043802142/34.
Texte intégralStillman, Anthony D. « Targeting Sphingosine Kinase 2 as a Treatment for Cholangiocarcinoma ». VCU Scholars Compass, 2019. https://scholarscompass.vcu.edu/etd/6067.
Texte intégralGupta, Snehalata. « Molecular interactions among PAP-1, SPHs and proPO in activation of prophenoloxidase ». 2004. http://digital.library.okstate.edu/etd/umi-okstate-1040.pdf.
Texte intégralLivres sur le sujet "SphK-1"
O'Brien, Edel, et Catherine Deegan. My Wellbeing Journey 1 : For Junior Cycle SPHE. M.H. Gill & Co. U. C., 2019.
Trouver le texte intégralHealthy Lifestyles 1 : SPHE Activities for First Year Students. M.H. Gill & Co. U. C., 2008.
Trouver le texte intégralO'Brien, Edel, et Catherine Deegan. New Healthy Lifestyles 1 : SPHE Activities for First Year. M.H. Gill & Co. U. C., 2014.
Trouver le texte intégralParamashivam, SPH Nithyananda. Nithya Katha 1 : Stories from the Divine Discourses of the SPH Nithyananda Paramashivam. KAILASA's Nithyananda Hindu University Press, 2011.
Trouver le texte intégralChapitres de livres sur le sujet "SphK-1"
Bart, Arnaud, Thibault Macherel, Giovanni De Cesare, Sean Mulligan et Khalid Essyad. « Vortex Siphon – From 1:1 Scale Physical Model to SPH Simulation and Prototype ». Dans Advances in Hydroinformatics, 795–807. Singapore : Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-5436-0_62.
Texte intégralActes de conférences sur le sujet "SphK-1"
Drosos, Z., H. Gevensleben, S. Kommoss, T. Karn, U. Holtrich, M. Graeser-Mayer, M. Anglesio, A. El-Balat, A. Rody et L. Hanker. « EP833 The prognostic impact of sphingosine-kinase 1 expression (SphK1) on ovarian cancer ». Dans ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.882.
Texte intégralHanker, LC, Z. Drosos, S. Kommoss, T. Karn, U. Holtrich, M. Graeser-Mayer, M. Anglesio, A. El-Balat, A. Rody et H. Gevensleben. « Expression of Sphingosine-Kinase 1 (SPHK1) as a prognostic factor in ovarian cancer ». Dans 62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe – DGGG'18. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1671643.
Texte intégralBeach, Jessica A., Paul-Joseph Aspuria, Dong-Joo Cheon, Maricel C. Gozo, Beth Y. Karlan et Sandra Orsulic. « Abstract B09 : Sphingosine kinase 1 (SPHK1) is a novel mediator of tumor-stroma interaction in ovarian cancer ». Dans Abstracts : AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment ; February 26 — March 1, 2014 ; San Diego, CA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.chtme14-b09.
Texte intégralRafiee, Ashkan, Sharen Cummins, Murray Rudman et Krish Thiagarajan. « The Effect of Pressure Solution in SPH Simulations of Sloshing Flow ». Dans ASME 2011 30th International Conference on Ocean, Offshore and Arctic Engineering. ASMEDC, 2011. http://dx.doi.org/10.1115/omae2011-49215.
Texte intégralKawashima, Yoichi, Yuzuru Sakai et Nobuki Yamagata. « Large Deformation Analysis by Smoothed Particle Hydrodynamics ». Dans ASME 2006 Pressure Vessels and Piping/ICPVT-11 Conference. ASMEDC, 2006. http://dx.doi.org/10.1115/pvp2006-icpvt-11-93612.
Texte intégralYamagata, Nobuki, Yuzuru Sakai et Pedro Marcal. « Elastic-Plastic and Frature Analysis of Mobile Phones Using SPH ». Dans ASME 2006 Pressure Vessels and Piping/ICPVT-11 Conference. ASMEDC, 2006. http://dx.doi.org/10.1115/pvp2006-icpvt-11-93614.
Texte intégralKruisbrink, A. Ch H., H. P. Morvan et F. R. Pearce. « Progress in Smoothed Particle Hydrodynamics to Simulate Bearing Chambers ». Dans ASME Turbo Expo 2014 : Turbine Technical Conference and Exposition. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/gt2014-26403.
Texte intégralVepa, Kameswara S., Diederik Van Nuffel, Wim Van Paepegem, Joris Degroote et Jan Vierendeels. « Comparative Study of Slamming Loads on Cylindrical Structures ». Dans ASME 2011 30th International Conference on Ocean, Offshore and Arctic Engineering. ASMEDC, 2011. http://dx.doi.org/10.1115/omae2011-49408.
Texte intégralPiwarski, Sean A., Tyler A. Allen, Dadong Zhang, Alexander B. Sibley, Patrick Healy, Brendon M. Patierno, Bonnie L. LaCroix et al. « Abstract PO-100 : Ancestry-related variation in Sphingosine Kinase Type 1-Interacting Protein (SKIP) and Sphingosine Kinase 1 (SPHK1) and response to secondary hormonal therapy in metastatic castration-resistant prostate cancer ». Dans Abstracts : AACR Virtual Conference : Thirteenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved ; October 2-4, 2020. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7755.disp20-po-100.
Texte intégralNguyen, Nhu, Krish P. Thiagarajan et Matthew Cameron. « Validation Study of Smoothed Particle Hydrodynamics in Fluid and Structure Interaction and the Comparison to Boundary Element Method ». Dans ASME 2017 36th International Conference on Ocean, Offshore and Arctic Engineering. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/omae2017-62285.
Texte intégralRapports d'organisations sur le sujet "SphK-1"
Nelson, Jennifer, Luis Tejerina, Alexandre Bagolle, Donghyun Kang, Elisa Martinez, Pablo Orefice, Myrna Marti et al. Digital Health For All : Social Protection and Health Division Regional Policy Dialogue Report 2022. Inter-American Development Bank, novembre 2022. http://dx.doi.org/10.18235/0004575.
Texte intégral